Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The study will be performed as an open-label, randomised, single-dose, two-sequence,
four-period replicated crossover design. A total of 72 Japanese healthy male subjects will be
randomised to 2 groups. The subjects are administrated either T80/A5/H12.5 mg FDC tablet once
or T80/A5 mg FDC tablet and hydrochlorothiazide (HCTZ) 12.5 mg tablet once in each period.
The length of admission will be 7 days in each period.